Home Data Calendar Blog

BBIO

Tables

		2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2019-12-31	2019-09-30
Common Stock Value		0.18	0.17	0.17	0.16	0.16	0.15	0.15	0.15	0.15	0.15	0.15	0.12	0.12	0.12	0.12
Weighted Average Number Of Diluted Shares Outstanding		163.31	160.54	152.65	NA	147.94	146.68	145.88	NA	146.66	146.75	NA	NA	NA	NA	NA
Weighted Average Number Of Shares Outstanding Basic		163.31	160.54	152.65	NA	147.94	146.68	145.88	NA	146.66	146.75	NA	NA	NA	NA	NA
Weighted Average Number Of Share Outstanding Basic And Diluted		NA	NA	NA	NA	NA	NA	145.88	NA	146.66	146.75	138.63	NA	118.17	NA	117.07
Earnings Per Share Basic		-1.08	-0.98	-0.92	-0.92	-0.93	-0.07	-1.35	-1.02	-1.06	-0.66	NA	NA	NA	NA	NA
Earnings Per Share Diluted		-1.08	-0.98	-0.92	-0.92	-0.93	-0.07	-1.35	-1.02	-1.06	-0.66	NA	NA	NA	NA	NA
Earnings Per Share Basic And Diluted		NA	NA	NA	NA	NA	NA	-1.35	-1.02	-1.06	-0.66	-1.18	-1.01	-0.98	-0.62	-0.51

		2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2019-12-31	2019-09-30
Revenue From Contract With Customer Excluding Assessed Tax		4.09	1.64	1.83	1.87	0.34	73.75	1.69	12.89	2.34	54.02	0.46	0.12	8.13	13.82	26.74
Revenues		4.09	1.64	1.83	1.87	0.34	73.75	1.69	12.89	2.34	54.02	0.46	0.12	8.13	13.82	26.74
Cost Of Revenue		0.60	0.60	NA	NA	0.74	0.70	NA	1.17	1.45	0.11	NA	NA	NA	NA	NA
Cost Of Goods And Services Sold		0.60	0.60	NA	NA	0.74	0.70	NA	1.17	1.45	0.11	NA	NA	NA	NA	NA
Costs And Expenses		161.78	147.74	127.99	131.10	129.45	153.92	175.37	178.50	151.84	148.04	167.97	127.61	128.07	NA	NA
Research And Development Expense		125.14	107.49	92.86	90.90	92.51	108.40	107.65	122.20	104.31	101.96	122.56	90.17	92.05	57.48	55.28
Selling General And Administrative Expense		35.78	36.12	31.11	31.86	31.19	36.43	43.71	54.75	46.08	45.97	45.41	37.44	36.02	NA	NA
Operating Income Loss		-157.69	-146.10	-126.16	-129.23	-129.12	-80.18	-173.68	-165.61	-149.50	-94.02	-167.50	-127.49	-119.94	-78.64	-54.53
Interest Expense		20.31	20.59	20.12	19.99	19.82	20.28	20.34	15.13	11.07	10.84	9.74	10.96	10.93	3.04	2.11
Interest Expense Debt		8.56	8.55	8.55	8.54	8.54	8.53	8.53	8.52	8.51	8.51	7.10	NA	8.21	NA	NA
Interest Paid Net		22.09	6.68	22.06	6.87	22.14	6.63	18.81	1.53	17.43	1.90	8.91	2.04	9.16	1.76	1.75
Allocated Share Based Compensation Expense		27.23	27.18	23.48	22.58	18.66	28.30	24.28	22.51	16.13	32.03	34.90	12.15	17.70	10.01	5.78
Profit Loss		-179.49	-160.70	-142.73	-140.57	-140.19	-2.56	-201.33	-152.28	-161.02	-102.07	-171.08	-135.03	-130.17	-84.15	-60.66
Comprehensive Income Net Of Tax		-177.03	-157.82	-139.84	-137.57	-137.26	-9.90	-196.65	-147.33	-155.95	-96.25	-163.33	-120.25	-116.26	-56.05	-60.51
Net Income Loss Available To Common Stockholders Basic		-177.00	-157.90	-140.16	-137.59	-137.34	-9.86	-196.40	-147.18	-155.94	-96.35	-163.08	-119.98	-115.86	-73.46	-59.98

		2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2019-12-31	2019-09-30
Assets		655.01	503.66	625.68	623.04	728.74	862.23	813.15	1012.79	781.52	1081.49	1093.31	703.59	787.69	631.68	640.53
Liabilities		1848.74	1853.30	1839.29	1867.96	1859.11	1877.25	1853.84	1878.37	1517.40	1537.11	1481.40	595.70	569.31	155.70	116.26
Liabilities And Stockholders Equity		655.01	503.66	625.68	623.04	728.74	862.23	813.15	1012.79	781.52	1081.49	1093.31	703.59	787.69	631.68	640.53
Stockholders Equity		-1207.54	-1362.02	-1225.66	-1254.62	-1138.42	-1025.53	-1041.00	-870.41	-743.40	-464.29	-395.29	57.91	163.76	408.45	459.76

		2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2019-12-31	2019-09-30
Assets Current		587.67	432.88	552.70	548.85	642.22	771.28	716.23	888.86	639.71	909.87	945.11	642.82	745.38	568.62	558.15
Cash And Cash Equivalents At Carrying Value		505.21	302.44	407.37	376.69	483.24	470.10	371.55	393.77	180.35	378.42	471.18	356.08	366.97	363.77	413.97
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents		524.14	324.64	435.11	416.88	485.79	472.65	374.19	396.37	183.08	381.13	473.77	358.68	NA	NA	NA
Marketable Securities Current		NA	30.87	34.12	51.58	75.08	218.47	261.90	393.74	419.26	459.24	447.94	251.01	343.71	182.22	NA
Prepaid Expense And Other Assets Current		22.58	20.55	25.14	21.92	25.66	32.75	34.02	32.45	31.93	26.67	25.53	35.73	26.70	22.63	22.10
Equity Securities Fv Ni		38.05	50.49	49.80	43.65	33.66	27.14	37.77	49.15	NA	NA	NA	NA	NA	NA	NA
Available For Sale Securities Debt Securities		NA	318.54	430.32	413.59	525.67	475.76	520.31	626.84	488.91	775.59	863.27	517.45	609.39	521.10	554.55

		2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2019-12-31	2019-09-30
Amortization Of Intangible Assets		0.60	0.60	0.60	0.60	0.60	0.60	0.90	1.30	0.70	NA	NA	NA	NA	NA	NA
Property Plant And Equipment Net		12.41	13.05	13.57	14.57	15.60	16.87	17.18	30.07	27.74	26.27	22.82	20.32	16.18	5.62	2.98
Intangible Assets Net Excluding Goodwill		26.92	27.52	28.11	28.71	29.31	29.91	30.48	44.93	46.20	NA	NA	NA	NA	NA	NA
Finite Lived Intangible Assets Net		26.92	27.52	28.11	28.71	29.31	29.91	30.48	44.93	46.20	NA	NA	NA	NA	NA	NA
Other Assets Noncurrent		18.68	20.40	20.77	20.22	29.87	31.32	35.33	33.03	33.05	49.80	30.18	23.93	16.48	26.29	2.60
Equity Securities Fv Ni		38.05	50.49	49.80	43.65	33.66	27.14	37.77	49.15	NA	NA	NA	NA	NA	NA	NA
Available For Sale Debt Securities Amortized Cost Basis		NA	318.47	430.33	413.92	526.02	476.19	520.69	626.98	488.89	775.56	863.32	517.26	608.93	520.85	554.39

		2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2019-12-31	2019-09-30
Liabilities Current		106.06	110.12	96.60	121.43	119.19	141.16	103.46	135.07	95.82	131.91	94.73	95.65	75.71	60.38	39.86
Accounts Payable Current		4.47	3.87	4.08	11.56	10.16	8.79	10.11	11.88	12.04	22.33	10.34	8.95	9.84	8.85	10.27
Other Accrued Liabilities Current		NA	6.23	22.22	25.19	23.84	31.98	24.78	30.28	14.61	21.18	18.25	13.35	NA	3.02	3.22

		2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2019-12-31	2019-09-30
Long Term Debt Noncurrent		441.72	440.50	435.76	430.99	NA	NA	434.11	430.75	103.14	102.61	90.76	92.42	93.39	91.79	75.02
Minority Interest		12.40	12.05	12.26	11.28	10.43	12.02	-0.03	3.41	4.56	6.80	5.93	48.35	52.06	65.28	61.94
Other Liabilities Noncurrent		11.79	13.33	17.50	26.64	28.23	28.63	26.83	22.07	27.58	13.27	11.61	9.52	13.47	3.53	1.39
Operating Lease Liability Noncurrent		9.81	10.92	11.90	12.27	13.00	14.28	15.49	17.43	18.68	18.02	13.86	14.68	8.24	NA	NA

		2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2019-12-31	2019-09-30
Stockholders Equity		-1207.54	-1362.02	-1225.66	-1254.62	-1138.42	-1025.53	-1041.00	-870.41	-743.40	-464.29	-395.29	57.91	163.76	408.45	459.76
Stockholders Equity Including Portion Attributable To Noncontrolling Interest		-1195.14	-1349.97	-1213.41	-1243.34	-1127.98	-1013.51	-1041.02	-867.00	-738.84	-457.49	-389.37	106.26	215.81	473.73	521.70
Common Stock Value		0.18	0.17	0.17	0.16	0.16	0.15	0.15	0.15	0.15	0.15	0.15	0.12	0.12	0.12	0.12
Additional Paid In Capital Common Stock		1459.60	1128.10	1106.63	938.70	917.33	892.96	867.60	841.53	821.22	799.68	767.12	1021.34	1006.94	848.11	826.06
Retained Earnings Accumulated Deficit		-2392.35	-2215.35	-2057.45	-1918.15	-1780.56	-1643.22	-1633.36	-1436.97	-1289.79	-1133.85	-1037.51	-888.75	-768.77	-440.03	-366.57
Accumulated Other Comprehensive Income Loss Net Of Tax		0.03	0.06	-0.01	-0.33	-0.35	-0.43	-0.38	-0.13	0.02	0.04	-0.06	0.19	0.46	0.25	NA
Treasury Stock Value		275.00	275.00	275.00	275.00	275.00	275.00	275.00	275.00	275.00	130.31	125.00	75.00	NA	NA	NA
Minority Interest		12.40	12.05	12.26	11.28	10.43	12.02	-0.03	3.41	4.56	6.80	5.93	48.35	52.06	65.28	61.94
Stock Issued During Period Value New Issues		NA	1.03	143.02	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	366.24
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value		24.23	24.61	24.33	NA	23.23	23.90	25.42	NA	16.90	32.51	19.84	NA	11.75	NA	NA

		2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2019-12-31	2019-09-30
Net Cash Provided By Used In Operating Activities		-145.23	-113.35	-144.32	-93.24	-135.16	-30.45	-160.63	-133.90	-121.56	-91.71	-150.76	-96.26	-131.68	-76.20	-50.00
Net Cash Provided By Used In Investing Activities		37.68	4.12	12.30	17.96	146.86	149.70	138.62	21.80	58.97	0.46	-282.05	83.02	-45.05	-16.90	-197.34
Net Cash Provided By Used In Financing Activities		307.04	-1.23	150.25	6.38	1.45	-20.80	-0.16	325.38	-135.46	-1.39	547.91	4.53	2.78	42.90	367.51

		2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2019-12-31	2019-09-30
Net Cash Provided By Used In Operating Activities		-145.23	-113.35	-144.32	-93.24	-135.16	-30.45	-160.63	-133.90	-121.56	-91.71	-150.76	-96.26	-131.68	-76.20	-50.00
Profit Loss		-179.49	-160.70	-142.73	-140.57	-140.19	-2.56	-201.33	-152.28	-161.02	-102.07	-171.08	-135.03	-130.17	-84.15	-60.66
Depreciation Depletion And Amortization		1.64	1.64	1.63	1.66	1.65	1.58	1.88	1.53	0.27	3.49	0.57	0.43	-1.01	NA	NA
Increase Decrease In Accounts Payable		0.69	-0.30	-3.80	1.38	1.36	-1.28	-1.81	1.47	-11.66	11.23	1.79	-1.28	-3.44	-1.42	-3.38
Share Based Compensation		22.60	27.18	21.91	21.79	17.36	28.29	24.12	19.77	16.04	30.11	33.58	12.15	17.70	10.01	5.78

		2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2019-12-31	2019-09-30
Net Cash Provided By Used In Investing Activities		37.68	4.12	12.30	17.96	146.86	149.70	138.62	21.80	58.97	0.46	-282.05	83.02	-45.05	-16.90	-197.34
Payments To Acquire Property Plant And Equipment		0.43	0.43	0.01	0.80	0.76	2.40	0.86	2.54	6.46	2.29	1.96	2.15	0.55	1.75	0.38

		2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2019-12-31	2019-09-30
Net Cash Provided By Used In Financing Activities		307.04	-1.23	150.25	6.38	1.45	-20.80	-0.16	325.38	-135.46	-1.39	547.91	4.53	2.78	42.90	367.51

		2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2019-12-31	2019-09-30
Revenues		4.09	1.64	1.83	1.87	0.34	73.75	1.69	12.89	2.34	54.02	0.46	0.12	8.13	13.82	26.74
Bristol Myers Squibb Company, Navire Pharma Inc, Research And Development Expense, License And Collaboration Agreement		NA	1.50	1.70	1.40	-0.10	3.20	NA	NA	NA	NA	NA	NA	NA	NA	NA
Bristol Myers Squibb Company, Navire Pharma Inc, Sales, License And Collaboration Agreement		1.30	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Bristol Myers Squibb Company, Navire Pharma Inc, License, License Agreement		1.70	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Lian Bio, Navire Pharma Inc, License, License Agreement		1.10	NA	NA	NA	0.30	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Bristol Myers Squibb Company, Navire Pharma Inc, License And Collaboration Agreement		NA	NA	NA	1.40	-0.10	73.40	NA	NA	NA	NA	NA	NA	NA	NA	NA
Lian Bio, License, License Agreement		NA	NA	NA	NA	0.30	NA	NA	0.00	0.00	8.50	NA	NA	NA	NA	NA
License		NA	NA	NA	NA	NA	NA	0.23	10.84	1.58	53.04	0.46	-0.13	8.00	NA	NA
License And Service		NA	NA	1.83	1.77	0.34	73.75	0.23	10.84	1.58	53.04	NA	NA	NA	NA	NA
Product		NA	NA	NA	0.10	0.00	0.00	1.46	2.05	0.76	0.99	NA	NA	NA	NA	NA
Revenue From Contract With Customer Excluding Assessed Tax		4.09	1.64	1.83	1.87	0.34	73.75	1.69	12.89	2.34	54.02	0.46	0.12	8.13	13.82	26.74
Bristol Myers Squibb Company, Navire Pharma Inc, Research And Development Expense, License And Collaboration Agreement		NA	1.50	1.70	1.40	-0.10	3.20	NA	NA	NA	NA	NA	NA	NA	NA	NA
Bristol Myers Squibb Company, Navire Pharma Inc, Sales, License And Collaboration Agreement		1.30	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Bristol Myers Squibb Company, Navire Pharma Inc, License, License Agreement		1.70	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Lian Bio, Navire Pharma Inc, License, License Agreement		1.10	NA	NA	NA	0.30	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Bristol Myers Squibb Company, Navire Pharma Inc, License And Collaboration Agreement		NA	NA	NA	1.40	-0.10	73.40	NA	NA	NA	NA	NA	NA	NA	NA	NA
Lian Bio, License, License Agreement		NA	NA	NA	NA	0.30	NA	NA	0.00	0.00	8.50	NA	NA	NA	NA	NA
License		NA	NA	NA	NA	NA	NA	0.23	10.84	1.58	53.04	0.46	-0.13	8.00	NA	NA
License And Service		NA	NA	1.83	1.77	0.34	73.75	0.23	10.84	1.58	53.04	NA	NA	NA	NA	NA
Product		NA	NA	NA	0.10	0.00	0.00	1.46	2.05	0.76	0.99	NA	NA	NA	NA	NA

Plots across concepts

Line plots across dimensions of each concept